MoonLake Immunotherapeutics entered into an underwriting agreement to issue and sell 8 million Class A ordinary shares at a public offering price of $50 per share, with expected gross proceeds of $460 million. The company also announced positive results from its Phase 2 MIRA trial for hidradenitis suppurativa treatment.